crackedtooth schreef:
Fase 2a: start 4 nov 2005
patients will receive MEM 1003 or placebo for a period of 12 weeks, which will be followed by a four week single-blind placebo treatment.
FAse 1:
\In September 2005, Memory Pharmaceuticals completed dosing in a single center, randomized, double-blind, placebo controlled safety and tolerability study of MEM 1003 in 81 Alzheimer's patients. The Company has also completed a Phase 1 clinical trial in 125 healthy volunteers in the United Kingdom to evaluate the potential cardiovascular impact and side effect profile produced by single and multiple doses of MEM 1003. The Company plans to announce results from the safety and tolerability study during the fourth quarter of 2005.
About the Company
in december dus alleen of het middel veilig is...